On Friday, Linn Co, LLC (NASDAQ:LNCO)’s shares surged 3.19% to $11, as Linn Co and LINN Energy, LLC (LINE), declared that administration will host a conference call on Wednesday, April 29, 2015, at 10 a.m. Central (11 a.m. Eastern) to talk about the Company’s first quarter 2015 results. Prepared remarks by Mark E. Ellis, Chairman, President and Chief Executive Officer, and Kolja Rockov, Executive Vice President and Chief Financial Officer, will be followed by a question and answer session.
LinnCo, LLC, through its limited liability company interests in Linn Energy, LLC, focuses on the attainment and development of oil and natural gas properties in the United States. The company was founded in 2012 and is headquartered in Houston, Texas.
Enerplus Corporation (NYSE:ERF)’s shares gained 3.02% to $11.58, during the last trading session on Friday, as Enerplus Corporation will be releasing our operating and financial results for the first quarter of 2015 at 4:00 AM MT (6:00 AM ET) on Friday, May 8, 2015.
Enerplus Corporation, together with auxiliaries, engages in the exploration and development of crude oil and natural gas in the United States and Canada. The company primarily has interests in about 162,000 net acres of lands comprising about 77,000 net acres targeting the Stacked Mannville zones and 85,000 net acres targeting the Duvernay formation in the Deep Basin region, Canada.
At the end of Friday’s trade, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s shares gained 2.99% to $182.68, as a biopharmaceutical company, declared that the European Commission (EC) has approved updates to the EU label for the therapeutic indication of Soliris® (eculizumab) in the treatment of paroxysmal nocturnal haemoglobinuria (PNH) to now comprise patients without a history of transfusion. With this approval, the revised Summary of Product Characteristics (SmPC) now indicates that evidence of clinical benefit is demonstrated in patients with high disease activity as defined by elevated haemolysis (LDH ≥1.5x ULN) and the presence of related clinical symptom(s), such as fatigue, haemoglobinuria, abdominal pain, shortness of breath, anaemia, major adverse vascular event (counting thrombosis), dysphagia or erectile dysfunction.
Additionally, the atypical haemolytic uraemic syndrome (aHUS) section of the EU label has been updated to comprise new efficacy data that specify that longer-term treatment with Soliris was associated with a greater proportion of patients achieving clinically noteworthy benefits, in addition to new information on the risks associated with treatment discontinuation. When the European Medicines Agency (EMA) approved Soliris for the treatment of patients with aHUS in 2011, the Clinical Particulars section of the SmPC (section 4) stated that Soliris treatment is “recommended to continue for the patient’s lifetime, unless the discontinuation of Soliris is clinically indicated,” as described in the Special warnings and precautions for use subsection. The updated label (section 4.4) has been revised to add more information on the risks of treatment discontinuation, counting that “TMA complications have been observed as early as 4 weeks and up to 127 weeks following discontinuation of Soliris treatment in some patients. Discontinuation of treatment should only be considered if medically justified.” The revised label also states that “monitoring may be insufficient to predict or prevent severe thrombotic microangiopathy (TMA) complications in patients who suspended Soliris treatment.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
Finally, Align Technology Inc. (NASDAQ:ALGN), ended its Friday’s trading session with 2.98% gain, and closed at $54.29, as Align Technology declared that the Company and ClearCorrect Operating, LLC have agreed to resolve the pending Remanded Enforcement Proceeding before the International Trade Commission (ITC). The parties to this contract are Align, ClearCorrect US, ClearCorrect Pakistan (Private), Ltd., Mudassar Rathore; Waqas Wahab; Asim Waheed; and Nadeem Arif. The resolution will be dependent on the outcome of the pending appeal before the Federal Circuit in the Infringement Action.
Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) services for use in dentistry, orthodontics, and dental records storage in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
